Attached files

file filename
EX-32.1 - EX-32.1 - Karyopharm Therapeutics Inc.d529132dex321.htm
EX-31.2 - EX-31.2 - Karyopharm Therapeutics Inc.d529132dex312.htm
EX-31.1 - EX-31.1 - Karyopharm Therapeutics Inc.d529132dex311.htm
EX-23.1 - EX-23.1 - Karyopharm Therapeutics Inc.d529132dex231.htm
EX-21.1 - EX-21.1 - Karyopharm Therapeutics Inc.d529132dex211.htm
EX-10.30 - EX-10.30 - Karyopharm Therapeutics Inc.d529132dex1030.htm
10-K - 10-K - Karyopharm Therapeutics Inc.d529132d10k.htm

Exhibit 12.1

STATEMENT REGARDING COMPUTATION OF CONSOLIDATED RATIOS OF EARNINGS TO FIXED CHARGES AND RATIOS OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS

 

     Fiscal Year Ended December 31,  
     2017     2016     2015     2014     2013  

Loss from operations

     (128,984     (110,732     (119,076     (75,846     (33,950

add: Fixed charges (see below)

     399       383       344       173       58  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Pre-tax loss from continuing operations plus fixed charges

     (128,585     (110,349     (118,732     (75,673     (33,892

Fixed charges:

          

Interest expense on indebtedness

     —         —         —         —         —    

Interest expense on portion of rent expense representative of interest

     399       383       344       173       58  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total fixed charges

     399       383       344       173       58  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Ratio of earnings to fixed charges

     —         —         —         —         —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Deficiency of earnings available to cover fixed charges

     (128,984     (110,732     (119,076     (75,846     (33,950
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

$ in thousands